Pharmacokinetics of a Single Oral Dose of the Mek1/2 Inhibitor Selumetinib in Subjects With End‐stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

DOI: 10.1002/jcph.848

,

Issn Print: 0091-2700

Publication Date: 2017/05/01

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

Angela W. Dymond; Paul Martin; Karen So; Yifan Huang; Paul Severin; Victoria Holmes; Gabriella Mariani; Thomas Marbury

Author Information: AstraZeneca


		Checking for direct PDF access through Ovid

View on Journal Site

Abstract unavailable for this article.


		Loading Related Articles